SVA vs. TH, ONC, HBP, BCT, MBX, APS, MDNA, FRX, HLS, and EDT
Should you be buying Sernova stock or one of its competitors? The main competitors of Sernova include Theratechnologies (TH), Oncolytics Biotech (ONC), Helix BioPharma (HBP), BriaCell Therapeutics (BCT), Microbix Biosystems (MBX), Aptose Biosciences (APS), Medicenna Therapeutics (MDNA), Fennec Pharmaceuticals (FRX), HLS Therapeutics (HLS), and Spectral Medical (EDT). These companies are all part of the "medical" sector.
Sernova (TSE:SVA) and Theratechnologies (TSE:TH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.
In the previous week, Sernova and Sernova both had 1 articles in the media. Theratechnologies' average media sentiment score of 1.05 beat Sernova's score of -0.99 indicating that Theratechnologies is being referred to more favorably in the news media.
0.1% of Sernova shares are owned by institutional investors. Comparatively, 50.7% of Theratechnologies shares are owned by institutional investors. 12.7% of Sernova shares are owned by company insiders. Comparatively, 6.3% of Theratechnologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Theratechnologies has higher revenue and earnings than Sernova. Sernova is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks.
Sernova has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, Theratechnologies has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500.
Theratechnologies received 261 more outperform votes than Sernova when rated by MarketBeat users. However, 88.89% of users gave Sernova an outperform vote while only 63.44% of users gave Theratechnologies an outperform vote.
Sernova currently has a consensus target price of C$1.50, suggesting a potential upside of 368.75%. Theratechnologies has a consensus target price of C$5.50, suggesting a potential upside of 210.73%. Given Sernova's higher probable upside, analysts plainly believe Sernova is more favorable than Theratechnologies.
Sernova has a net margin of 0.00% compared to Theratechnologies' net margin of -23.04%. Sernova's return on equity of -183.58% beat Theratechnologies' return on equity.
Summary
Theratechnologies beats Sernova on 10 of the 16 factors compared between the two stocks.
Get Sernova News Delivered to You Automatically
Sign up to receive the latest news and ratings for SVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
